Alcon acquires Neurotech for $550 million
ALC•Alcon acquired Neurotech Pharmaceuticals for $550 million, adding ENCELTO to its retina portfolio. The deal may include contingent payments and is expected to slightly dilute core diluted EPS in 2027, then be accretive thereafter.
1. Deal terms and outlook
Alcon acquired Neurotech Pharmaceuticals for $550 million, with additional contingent payments potentially due upon achievement of commercial milestones. The transaction is expected to modestly boost net sales growth, slightly dilute core diluted EPS in 2027 and be accretive thereafter.
2. ENCELTO treatment
The acquisition adds ENCELTO, the only FDA-approved treatment for adults with idiopathic Macular Telangiectasia Type 2, a progressive retinal disease. The therapy received FDA approval in March 2025 and is available only in the U.S.
